10 results about "Growth hormone secretion" patented technology

The invention discloses a composition for promoting growth hormone secretion and nutrient absorption. The composition comprises gamma-aminobutyric acid, composite minerals, composite vitamins, lactobacillus fermentum and seasoning auxiliary materials. The preparation method comprises the following steps: (1) putting the weighed materials into a wet granulator, adding water according to the proportion, and granulating; (2) drying the granulated material, and controlling the moisture to be within 5%; and (3) adding seasoning auxiliary materials into the dried material particles, and mixing to obtain the composition. The composition provided by the invention provides enough nutrients while the gamma-aminobutyric acid promotes the secretion of growth hormones, so that the effects can be better exerted, and the aim of achieving a higher expected effect is achieved.

To provide a novel strain of Tetragenococcus halophilus having superior capability for producing ornithine and citrulline, thereby enabling the efficient production of ornithine and citrulline that are beneficial amino acids, and their application in the manufacture of food compositions, supplements, pharmaceuticals and the like suitable for maintaining or promoting health, including stimulation of growth hormone secretion, regulation of sleep-wake cycles, enhancement of liver function, rejuvenation of fatigued skin, reduction of mental stress, and recovery from physical fatigue.SOLUTION: Provided is a strain of Tetragenococcus halophilus KA12022 (Deposit Number: NITE P-03886).SELECTED DRAWING: Figure 4

The present specification discloses, as a specific embodiment of the present invention, a growth hormone secretion promoter comprising a somatostatin receptor subtype 5 ("SSTR5") antagonist as an active ingredient, and the like.

This invention discloses the use of at least one growth-active substance selected from (a) and (b) below, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof, or an analogue thereof, or an analogue thereof, in the preparation of a medicament, pharmaceutical composition, or formulation for improving, correcting, alleviating, controlling, treating, or preventing ophthalmic diseases or symptoms: (a) growth hormone; (b) a growth hormone secretion stimulant. By administering an effective amount of the growth-active substance to a patient, ophthalmological conditions, especially hyperopia and related symptoms, can be significantly improved, achieving the effect of preventing and treating hyperopia, with good safety and promising clinical application prospects. This invention also provides pharmaceutical compositions, formulations, and devices containing the above-mentioned growth-active substances.

The application discloses an evaluation method and system based on child growth hormone secretion data, and relates to the technical field of medical data processing.The method determines candidate points through robust outlier preliminary screening by acquiring a growth hormone concentration time sequence; extracts a concentration subsequence of a neighborhood window of the candidate points, calculates a dynamic time warping distance of the concentration subsequence from a preset pulse sequence by using a dynamic time warping algorithm, and converts the dynamic time warping distance into a pulse score; performs candidate point reservation, elimination or boundary undetermined point marking according to the score, and generates a first purified concentration sequence from the remaining points; obtains a first fitted concentration sequence by deconvolution reconstruction, and performs LB test on a residual sequence; if significant, performs flip verification based on a residual sum of squares improvement range on the boundary undetermined points in descending order of the score, obtains a third purified concentration sequence, and outputs an evaluation report.The application solves the problems of outlier elimination error and deconvolution system deviation through pulse morphological structure perception and residual feedback verification.

The invention discloses application of m6A demethylase FTO in pituitary endocrine tumors, and belongs to the technical field of biological medicine. Compared with the DGGH, the m6A level in the SGGH is obviously reduced, and the expression of m6A demethylase FTO in the SGGH subtype is increased. Inhibition of FTO in tumor cells significantly reduces hypoxia tolerance, weakens secretion of growth hormone, and enhances sensitivity to octreotide. The FTO-mediated m6A demethylation is unstable through DSP mRNA mediated by an m6A reader FMR1, so that the integrity of a desmosome structure is damaged, and the tumor hypoxia tolerance is enhanced. In the prior art, the targeted FTO-DSP-SSTR2 axis reduces growth hormone secretion, so that tumors are sensitive to octreotide treatment, the invention reveals the key effect of FTO in invasive growth hormone adenoma subtypes, and indicates that FTO may be used as a new treatment target of intractable / persistent SGGH.

This invention relates to the field of animal husbandry technology, specifically to a fermented compound herbal feed additive for lambs, its preparation method, and its application. The fermented compound herbal feed additive for lambs, by weight, comprises the following components: 10-20 parts of *Trifolium repens*, 10-20 parts of raw malt, 5-15 parts of *Astragalus membranaceus*, 5-15 parts of *Saposhnikovia divaricata*, 5-15 parts of *Medicated Leaven*, 5-15 parts of dried tangerine peel, 5-15 parts of green tangerine peel, 5-15 parts of *Dryopteris crassirhizoma*, 3-5 parts of stir-fried *Atractylodes macrocephala*, and 3-5 parts of calcined oyster shell. When added to the feed of pre-weaning lambs, the fermented herbal ingredients of this invention improve lamb growth performance, promote growth hormone secretion, enhance immunity, and alleviate lamb stress.

To provide a novel ghrelin secretion-enhancing composition.SOLUTION: The present invention provides a ghrelin secretion-enhancing composition containing a bacterium classified under Lactobacillus delbrueckii, and a composition used for one or more purposes selected from the group consisting of enhancement of growth hormone secretion, inhibition of brown adipose tissue function, enhancement of gastrointestinal motility, stimulation of gastric acid secretion, stimulation of pancreatic exocrine secretion, vasodilation, augmentation of myocardial contractility, and protection of cardiomyocytes.SELECTED DRAWING: None

The present invention relates to a screening method for diagnosing growth hormone deficiency in pediatric patients by using maxirelin. The present invention further provides the substance maxirelin for use in the diagnosis of growth hormone deficiency in pediatric patients. The method includes providing at least one blood sample collected from a subject within a range of about 15 to about 100 minutes after administration of maxirelin in an amount effective to induce secretion of growth hormone, measuring a growth hormone level for each blood sample, comparing the measured growth hormone levels to a single threshold, and determining whether the measured growth hormone levels are different from the single threshold. And diagnosing whether the subject has growth hormone deficiency based on a comparison of the growth hormone level in the at least one blood sample to the single threshold. The method of the invention is a stand-alone test, does not require repetition, and does not require additional growth hormone stimulation tests for reliable diagnosis of pediatric patients.

The present invention provides a plant extract composition for enhancing endogenous growth hormone secretion. The plant extract composition comprises a Mucuna pruriens extract and an Astragalus root extract. In the plant extract composition, the Mucuna pruriens extract and the Astragalus root extract exhibit a synergistic effect. Thus, the plant extract composition containing both the Mucuna pruriens extract and the Astragalus root extract (hereinafter referred to as the composition) can promote the secretion of endogenous growth hormone, thereby increasing growth hormone levels and effectively addressing the poor compliance issue associated with traditional injection methods.